Brought to you by 
Liquidia partners PRINT candidates with GlaxoSmithKline
27 Jun 2019
Executive Summary
In a multi-year arrangement, GlaxoSmithKline PLC has received exclusive rights to research and develop vaccines and inhaled therapeutics that incorporate nanotech firm Liquidia Technologies Inc.’s Particle Replication In Non-Wetting Templates (PRINT) nanoparticle manufacturing technology. GSK has an exclusive worldwide option on know-how and patents related to PRINT.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Pulmonary
-
Biotechnology
- Synthesis Technologies, Production Processes
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Liquidia partners PRINT candidates with GlaxoSmithKline
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice